VCN Biosciences SL, a wholly-owned subsidiary of Synthetic Biologics Inc. (NYSE American: SYN), is focused on the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.
Development of new agents for the treatment of cancer based on oncolytic adenoviruses
Technological platform based on oncolytic adenoviruses to generate virotherapeutic candidates
VCN Biosciences is a dynamic company passionate for cancer research
Virotherapy is a therapeutic approach for cancer treatment based on the use of viruses
-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, andidentify recommended Phase 2 dose (RP2D)-
-Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV)platform-
Follows recent announcement of planned acquisition of VCN Biosciences by Synthetic Biologics.
Read more ...VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer
Read more ...Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid TumorsLead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trialsDesigned for systemic delivery, high selectivity, and enhanced tumor accessVCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMASynthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time
For Immediate Release
Read more ...© Copyright 2022 VCNBiosciences